Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

NutriSystem (NTRI) Adopts Multi-Brand Strategy For 2018

Published 12/27/2017, 09:08 PM
Updated 07/09/2023, 06:31 AM

NutriSystem Inc. (NASDAQ:NTRI) has adopted a multi-brand strategy for Diet Season 2018, offering a series of healthy-structured weight loss options. These include NutriSystem for 2018 and South Beach Diet for 2018.

NutriSystem for 2018

It comprises two sub plans — NutriSystem Turbo13 and NutriSystem Turbo for Men.

The NutriSystem Turbo13 plan is a quick start weight loss plan. It includes Turbo TakeOff, a one-week jumpstart with specially designed foods, all-new NutriCurb bars, bestselling Turbo Shakes and the new TurboBoosters.

NutriSystem Turbo for Men program includes new Nutri-Pro shakes containing 20 grams of proteins along with increased snacking options. With its intake, men can lose up to 15 lbs and 7 inches in the first month.

South Beach Diet for 2018

South Beach Diet is a structured weight-loss plan, which offers a high-protein, low-carb, low-sugar approach in diet. It is a three-phased low carb approach, designed to burn fat, change metabolism and stimulate energy.
According to NutriSystem, the low-sugar and low-carb approach of South Beach has boosted its demand. Launched earlier this year, South Beach contributed $5 million to revenues in the third quarter.

The 2018 campaign will be carried out with the help of the company’s brand ambassadors, social influencers and customer success stories and integrated across television, digital and social media channels.

Market Trends in Weight-Loss Industry

Per a research done by Markets and Markets, the weight loss and weight management market is estimated to reach $245.51 billion by 2022 at a CAGR of 6.9%. The growth of this market is primarily attributed to the growing rate of obesity and increasing incidence of lifestyle diseases.

Looking at this data, we are optimistic on NutriSystem’s 2018 plans. The company expects its customized solutions, which can be ordered online, to witness significant customer adoption.

Share Price Performance

Over the last one year, NutriSystem has outperformed the broader industry . The company has gained 49.5% in this period compared with the broader industry’s gain of 27.3%.

Zacks Rank & Key Picks

NutriSystem carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the industry are Akari Therapeutics PLC. (NASDAQ:AKTX) , Bio-Rad Laboratories, Inc. (NYSE:BIO) and C.R. Bard Inc. (NYSE:BCR) . While Akari Theraputics and Bio-Rad sport a Zacks Rank #1 (Strong Buy), C.R. Bard Inc. (BCR) holds a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Akari’s projected EPS growth rate for the next quarter is 88.89%. Interestingly, over the past three quarters, the company has surpassed the Zacks Consensus Estimate by an average of 88.6%.

Bio-Rad’s projected EPS growth rate for the next quarter is 140.65%. The stock has rallied roughly 32% in the last year.

C.R. Bard’s projected EPS growth rate for the next year is 9.15%. The stock has rallied roughly 49.9% in the last one year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

C.R. Bard, Inc. (BCR): Free Stock Analysis Report

NutriSystem Inc (NTRI): Free Stock Analysis Report

Akari Therapeutics PLC (AKTX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.